Atlassian Co. (NASDAQ:TEAM – Get Free Report) CEO Scott Farquhar sold 8,241 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $177.14, for a total value of $1,459,810.74. Following the completion of the transaction, the chief executive officer now owns 341,727 shares in the company, valued at $60,533,520.78. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Scott Farquhar also recently made the following trade(s):
- On Wednesday, April 24th, Scott Farquhar sold 8,241 shares of Atlassian stock. The stock was sold at an average price of $199.71, for a total transaction of $1,645,810.11.
- On Monday, April 22nd, Scott Farquhar sold 8,241 shares of Atlassian stock. The stock was sold at an average price of $193.35, for a total value of $1,593,397.35.
- On Friday, April 12th, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $207.36, for a total value of $1,708,853.76.
- On Thursday, March 28th, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $194.67, for a total transaction of $1,604,275.47.
- On Friday, March 22nd, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $192.73, for a total transaction of $1,588,287.93.
- On Monday, March 18th, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $197.25, for a total value of $1,625,537.25.
- On Monday, March 11th, Scott Farquhar sold 8,241 shares of Atlassian stock. The stock was sold at an average price of $214.32, for a total value of $1,766,211.12.
- On Friday, March 1st, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $207.85, for a total value of $1,712,891.85.
- On Monday, February 26th, Scott Farquhar sold 8,241 shares of Atlassian stock. The stock was sold at an average price of $204.79, for a total transaction of $1,687,674.39.
- On Tuesday, February 20th, Scott Farquhar sold 8,241 shares of Atlassian stock. The shares were sold at an average price of $204.63, for a total transaction of $1,686,355.83.
Atlassian Stock Down 2.7 %
Shares of NASDAQ TEAM traded down $4.77 during mid-day trading on Tuesday, hitting $172.30. 2,659,720 shares of the stock traded hands, compared to its average volume of 1,750,434. The stock has a fifty day moving average price of $199.36 and a 200-day moving average price of $206.52. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.07 and a current ratio of 1.07. The company has a market cap of $44.70 billion, a price-to-earnings ratio of -272.22 and a beta of 0.63. Atlassian Co. has a 52 week low of $128.02 and a 52 week high of $258.69.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of Atlassian during the third quarter valued at $26,000. Carmel Capital Partners LLC raised its position in Atlassian by 28.5% in the 3rd quarter. Carmel Capital Partners LLC now owns 257 shares of the technology company’s stock worth $52,000 after buying an additional 57 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in Atlassian by 271.0% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 371 shares of the technology company’s stock valued at $88,000 after acquiring an additional 271 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Atlassian by 255.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 405 shares of the technology company’s stock valued at $96,000 after acquiring an additional 291 shares during the last quarter. Finally, Operose Advisors LLC bought a new stake in shares of Atlassian in the third quarter worth approximately $99,000. 93.03% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on TEAM shares. William Blair reiterated an “outperform” rating on shares of Atlassian in a research report on Friday, February 2nd. Oppenheimer dropped their price target on Atlassian from $300.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday. Citigroup decreased their price objective on shares of Atlassian from $280.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, April 12th. The Goldman Sachs Group lifted their target price on shares of Atlassian from $188.00 to $215.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Finally, Truist Financial lowered their price objective on shares of Atlassian from $220.00 to $200.00 and set a “hold” rating on the stock in a research report on Friday. Ten equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $223.22.
View Our Latest Stock Analysis on TEAM
About Atlassian
Atlassian Corporation, through its subsidiaries, designs, develops, licenses, and maintains various software products worldwide. Its product portfolio includes Jira Software and Jira Work Management, a project management system that connects technical and business teams so they can better plan, organize, track and manage their work and projects; Confluence, a connected workspace that organizes knowledge across all teams to move work forward; and Trello, a collaboration and organization product that captures and adds structure to fluid and fast-forming work for teams.
Further Reading
- Five stocks we like better than Atlassian
- Why Invest in 5G? How to Invest in 5G Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Capture the Benefits of Dividend Increases
- Hilton Demonstrates Asset Light is Right for Investors
- Investing in large cap stocks: Diving into big caps
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Atlassian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlassian and related companies with MarketBeat.com's FREE daily email newsletter.